Loading…
Australian clinical-stage biotech developing RNA-based therapies (antisense oligonucleotides) for inherited eye diseases and other genetic disorders.
Australian clinical-stage biotech developing RNA-based therapies (antisense oligonucleotides) for inherited eye diseases and other genetic disorders.
Has no approved product, so money comes from raising capital and from Australian R&D tax incentive refunds, with partnership payments a possible later source.
In one line: An early-stage RNA-therapeutics biotech.
Moat: narrow (IP / patents). Proprietary RNA-targeting chemistry and patents on specific genetic targets protect pipeline candidates.
Headquarters: Perth, Australia · Founded: 2013
Size PYC Therapeutics (PYC.AX) is an Australia Health Care company (Pharmaceuticals: Major) with a market value of $1.28B, the 158th largest of 316 Australia companies the cockpit tracks. Shares closed at A$1.88 on 6 Nov 2026.
Performance Over six months the shares gained 30.6%, against -12.3% for the median peer and +4.1% for the Australia market (cap-weighted) — highest of 21 in its peer set.
Capital Return on invested capital runs 33.0 points below its cost of capital (9.5% WACC).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$0 | A$0 | A$0 | A$0 | A$0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -A$1.20M | -A$1.20M | -A$1.12M | -A$1.07M | -A$882,045 |
| EBITDA | -A$81.5M | -A$81.5M | -A$74.8M | -A$59.4M | -A$38.3M |
| Net income | -A$43.3M | -A$43.3M | -A$50.3M | -A$37.7M | -A$22.8M |
| Free cash flow | -A$45.1M | -A$45.1M | -A$52.5M | -A$38.9M | -A$24.9M |
| Capital expenditure | A$531,391 | A$531,391 | A$975,397 | A$307,044 | A$491,116 |
| Total debt | n/a | A$624,988 | A$1.02M | A$1.11M | A$315,487 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| PYC Therapeutics PYC.AX | $1.28B | +31% | n/a | n/a | n/a | n/a |
| Ionis Pharmaceuticals IONS | $6.55B | -48% | -7% | -68% | 7.7× | n/a |
| ProQR Therapeutics PRQR | n/a | -15% | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | $664M | -53% | -35% | -321% | 3.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PYC.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.7% | -6.2% | 3rd lowest of 21 |
| 6-month return | +30.6% | -12.3% | highest of 21 |
| Distance from 52-week high | -35.8% | -43.0% | 9th highest of 21 |
| ROIC minus cost of capital | -33.0 pp | -5.1 pp | 7th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | 617.6× | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | 13.3× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | 3.0× | 11.7% | +18.1% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | 111.4× | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | 417.6× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 5.0× | 4.0% | +27.9% |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | 4.0× | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 0.5× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 2.0× | 8.5% | -5.3% |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | 11.2× | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 3.4× | -2.4% | +13.8% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | 10.7× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 2.1× | 0.3% | -1.3% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | 10.0× | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.34B | -18% | +17% | 13% | 1.4× | -7.4% | +12.7% |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 36.2× | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 9.8× | 26.1% | +23.1% |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 3.5× | n/a | n/a |